✦ LIBER ✦

Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma

✍ Scribed by Alessandro Gozzetti; Alberto Fabbri; Stefania Oliva; Elena Marchini; Monica Bocchia; Marzia Defina; Francesco Lauria

Book ID: 119936217
Publisher: Elsevier
Year: 2010
Tongue: English
Weight: 115 KB
Volume: 10
Category: Article
ISSN: 2152-2650
DOI: 10.3816/clml.2010.n.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A modified regimen of pegylated liposoma

A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma

✍ Gabriel N. Waterman; Ori Yellin; Regina A. Swift; Russell Mapes; Benjamin Eades; 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 206 KB

Pegylated liposomal doxorubicin, melphal

Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma

✍ R García-Sanz; JM Hernández; A Sureda; J García-Laraña; F Prósper; A Alegre; A B 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract Melphalan & Prednisone (MP) is considered as the standard therapy for Multiple Myeloma (MM) patients not eligible for high‐dose therapy. Here, we report the results of a phase I–II study to evaluate the feasibility and efficacy of the association of PLD to the conventional MP regimen du

A modified regimen of pegylated liposoma

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

✍ James R. Berenson; Ori Yellin; Chien-Shing Chen; Ravi Patel; Alberto Bessudo; Ra 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB

Pegylated Liposomal Doxorubicin plus Bor

Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

✍ Bladé, Joan; Sonneveld, Pieter; San Miguel, Jesús F.; Sutherland, Heather J.; Ha 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 145 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Rapid early monoclonal protein reduction

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

✍ Jatin Shah; Joan Bladé; Pieter Sonneveld; Jean-Luc Harousseau; Keith Lantz; Anil 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB